Table of Content

1 Tumor Necrosis Factor Inhibitors Drug Market Overview
1.1 Tumor Necrosis Factor Inhibitors Drug Product Scope
1.2 Tumor Necrosis Factor Inhibitors Drug Segment by Type
1.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales by Type (2016 & 2021 & 2027)
1.2.2 Cimzia (Certolizumab Pegol)
1.2.3 Enbrel (Etanercept)
1.2.4 Humira ( Adalimumab)
1.2.5 Otezla (Apremilast)
1.2.6 Remicade (Infliximab)
1.2.7 Simponi (Golimumab)
1.3 Tumor Necrosis Factor Inhibitors Drug Segment by Application
1.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Others
1.4 Tumor Necrosis Factor Inhibitors Drug Market Estimates and Forecasts (2016-2027)
1.4.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Tumor Necrosis Factor Inhibitors Drug Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Tumor Necrosis Factor Inhibitors Drug Price Trends (2016-2027)

2 Tumor Necrosis Factor Inhibitors Drug Estimates and Forecasts by Region
2.1 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Tumor Necrosis Factor Inhibitors Drug Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2016-2021)
2.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region (2016-2021)
2.3 Global Tumor Necrosis Factor Inhibitors Drug Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Tumor Necrosis Factor Inhibitors Drug Estimates and Projections (2016-2027)
2.4.2 Europe Tumor Necrosis Factor Inhibitors Drug Estimates and Projections (2016-2027)
2.4.3 China Tumor Necrosis Factor Inhibitors Drug Estimates and Projections (2016-2027)
2.4.4 Japan Tumor Necrosis Factor Inhibitors Drug Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Estimates and Projections (2016-2027)
2.4.6 India Tumor Necrosis Factor Inhibitors Drug Estimates and Projections (2016-2027)

3 Global Tumor Necrosis Factor Inhibitors Drug Competition Landscape by Players
3.1 Global Top Tumor Necrosis Factor Inhibitors Drug Players by Sales (2016-2021)
3.2 Global Top Tumor Necrosis Factor Inhibitors Drug Players by Revenue (2016-2021)
3.3 Global Tumor Necrosis Factor Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Tumor Necrosis Factor Inhibitors Drug as of 2020)
3.4 Global Tumor Necrosis Factor Inhibitors Drug Average Price by Company (2016-2021)
3.5 Manufacturers Tumor Necrosis Factor Inhibitors Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Type
4.1 Global Tumor Necrosis Factor Inhibitors Drug Historic Market Review by Type (2016-2021)
4.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2016-2021)
4.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Type (2016-2021)
4.1.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Type (2016-2021)
4.2 Global Tumor Necrosis Factor Inhibitors Drug Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Type (2022-2027)
4.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Type (2022-2027)
4.2.3 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Type (2022-2027)

5 Global Tumor Necrosis Factor Inhibitors Drug Market Size by Application
5.1 Global Tumor Necrosis Factor Inhibitors Drug Historic Market Review by Application (2016-2021)
5.1.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2016-2021)
5.1.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Application (2016-2021)
5.1.3 Global Tumor Necrosis Factor Inhibitors Drug Price by Application (2016-2021)
5.2 Global Tumor Necrosis Factor Inhibitors Drug Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Tumor Necrosis Factor Inhibitors Drug Sales Forecast by Application (2022-2027)
5.2.2 Global Tumor Necrosis Factor Inhibitors Drug Revenue Forecast by Application (2022-2027)
5.2.3 Global Tumor Necrosis Factor Inhibitors Drug Price Forecast by Application (2022-2027)

6 North America Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures
6.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Company
6.1.1 North America Tumor Necrosis Factor Inhibitors Drug Sales by Company (2016-2021)
6.1.2 North America Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021)
6.2 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type
6.2.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2016-2021)
6.2.2 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2022-2027)
6.3 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application
6.3.1 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2016-2021)
6.3.2 North America Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2022-2027)

7 Europe Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures
7.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Company
7.1.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales by Company (2016-2021)
7.1.2 Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021)
7.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type
7.2.1 Europe Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2016-2021)
7.2.2 Europe Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2022-2027)
7.3 Europe Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application
7.3.1 Europe 148 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 148 Sales Breakdown by Application (2022-2027)

8 China Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures
8.1 China Tumor Necrosis Factor Inhibitors Drug Sales by Company
8.1.1 China Tumor Necrosis Factor Inhibitors Drug Sales by Company (2016-2021)
8.1.2 China Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021)
8.2 China Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type
8.2.1 China Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2016-2021)
8.2.2 China Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2022-2027)
8.3 China Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application
8.3.1 China 175 Sales Breakdown by Application (2016-2021)
8.3.2 China 175 Sales Breakdown by Application (2022-2027)

9 Japan Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures
9.1 Japan Tumor Necrosis Factor Inhibitors Drug Sales by Company
9.1.1 Japan Tumor Necrosis Factor Inhibitors Drug Sales by Company (2016-2021)
9.1.2 Japan Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021)
9.2 Japan Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type
9.2.1 Japan Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2016-2021)
9.2.2 Japan Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2022-2027)
9.3 Japan Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application
9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)

10 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures
10.1 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales by Company
10.1.1 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales by Company (2016-2021)
10.1.2 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021)
10.2 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type
10.2.1 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application
10.3.1 Southeast Asia K Pcs Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia K Pcs Sales Breakdown by Application (2022-2027)

11 India Tumor Necrosis Factor Inhibitors Drug Market Facts & Figures
11.1 India Tumor Necrosis Factor Inhibitors Drug Sales by Company
11.1.1 India Tumor Necrosis Factor Inhibitors Drug Sales by Company (2016-2021)
11.1.2 India Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021)
11.2 India Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type
11.2.1 India Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2016-2021)
11.2.2 India Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Type (2022-2027)
11.3 India Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application
11.3.1 India Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2016-2021)
11.3.2 India Tumor Necrosis Factor Inhibitors Drug Sales Breakdown by Application (2022-2027)

12 Company Profiles and Key Figures in Tumor Necrosis Factor Inhibitors Drug Business
12.1 Apogenix
12.1.1 Apogenix Corporation Information
12.1.2 Apogenix Business Overview
12.1.3 Apogenix Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Apogenix Tumor Necrosis Factor Inhibitors Drug Products Offered
12.1.5 Apogenix Recent Development
12.2 AryoGen Biopharma
12.2.1 AryoGen Biopharma Corporation Information
12.2.2 AryoGen Biopharma Business Overview
12.2.3 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.2.4 AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Products Offered
12.2.5 AryoGen Biopharma Recent Development
12.3 Bionovis
12.3.1 Bionovis Corporation Information
12.3.2 Bionovis Business Overview
12.3.3 Bionovis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Bionovis Tumor Necrosis Factor Inhibitors Drug Products Offered
12.3.5 Bionovis Recent Development
12.4 CASI Pharmaceuticals
12.4.1 CASI Pharmaceuticals Corporation Information
12.4.2 CASI Pharmaceuticals Business Overview
12.4.3 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.4.4 CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
12.4.5 CASI Pharmaceuticals Recent Development
12.5 Celltrion
12.5.1 Celltrion Corporation Information
12.5.2 Celltrion Business Overview
12.5.3 Celltrion Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Celltrion Tumor Necrosis Factor Inhibitors Drug Products Offered
12.5.5 Celltrion Recent Development
12.6 Celgene Corporation
12.6.1 Celgene Corporation Corporation Information
12.6.2 Celgene Corporation Business Overview
12.6.3 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Products Offered
12.6.5 Celgene Corporation Recent Development
12.7 Delenex Therapeutics
12.7.1 Delenex Therapeutics Corporation Information
12.7.2 Delenex Therapeutics Business Overview
12.7.3 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.7.4 Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Products Offered
12.7.5 Delenex Therapeutics Recent Development
12.8 Dexa Medica
12.8.1 Dexa Medica Corporation Information
12.8.2 Dexa Medica Business Overview
12.8.3 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Dexa Medica Tumor Necrosis Factor Inhibitors Drug Products Offered
12.8.5 Dexa Medica Recent Development
12.9 EPIRUS Biopharmaceuticals
12.9.1 EPIRUS Biopharmaceuticals Corporation Information
12.9.2 EPIRUS Biopharmaceuticals Business Overview
12.9.3 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.9.4 EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
12.9.5 EPIRUS Biopharmaceuticals Recent Development
12.10 Janssen Biotech
12.10.1 Janssen Biotech Corporation Information
12.10.2 Janssen Biotech Business Overview
12.10.3 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Products Offered
12.10.5 Janssen Biotech Recent Development
12.11 GlaxoSmithKline
12.11.1 GlaxoSmithKline Corporation Information
12.11.2 GlaxoSmithKline Business Overview
12.11.3 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.11.4 GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Products Offered
12.11.5 GlaxoSmithKline Recent Development
12.12 HanAll Biopharma
12.12.1 HanAll Biopharma Corporation Information
12.12.2 HanAll Biopharma Business Overview
12.12.3 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.12.4 HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Products Offered
12.12.5 HanAll Biopharma Recent Development
12.13 Intas Pharmaceuticals
12.13.1 Intas Pharmaceuticals Corporation Information
12.13.2 Intas Pharmaceuticals Business Overview
12.13.3 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
12.13.5 Intas Pharmaceuticals Recent Development
12.14 LEO Pharma
12.14.1 LEO Pharma Corporation Information
12.14.2 LEO Pharma Business Overview
12.14.3 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.14.4 LEO Pharma Tumor Necrosis Factor Inhibitors Drug Products Offered
12.14.5 LEO Pharma Recent Development
12.15 LG Life Sciences
12.15.1 LG Life Sciences Corporation Information
12.15.2 LG Life Sciences Business Overview
12.15.3 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.15.4 LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Products Offered
12.15.5 LG Life Sciences Recent Development
12.16 MedImmune
12.16.1 MedImmune Corporation Information
12.16.2 MedImmune Business Overview
12.16.3 MedImmune Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.16.4 MedImmune Tumor Necrosis Factor Inhibitors Drug Products Offered
12.16.5 MedImmune Recent Development
12.17 Momenta Pharmaceuticals
12.17.1 Momenta Pharmaceuticals Corporation Information
12.17.2 Momenta Pharmaceuticals Business Overview
12.17.3 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.17.4 Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
12.17.5 Momenta Pharmaceuticals Recent Development
12.18 Novartis
12.18.1 Novartis Corporation Information
12.18.2 Novartis Business Overview
12.18.3 Novartis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.18.4 Novartis Tumor Necrosis Factor Inhibitors Drug Products Offered
12.18.5 Novartis Recent Development
12.19 PROBIOMED
12.19.1 PROBIOMED Corporation Information
12.19.2 PROBIOMED Business Overview
12.19.3 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.19.4 PROBIOMED Tumor Necrosis Factor Inhibitors Drug Products Offered
12.19.5 PROBIOMED Recent Development
12.20 Reliance Life Sciences
12.20.1 Reliance Life Sciences Corporation Information
12.20.2 Reliance Life Sciences Business Overview
12.20.3 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.20.4 Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Products Offered
12.20.5 Reliance Life Sciences Recent Development
12.21 Sandoz
12.21.1 Sandoz Corporation Information
12.21.2 Sandoz Business Overview
12.21.3 Sandoz Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.21.4 Sandoz Tumor Necrosis Factor Inhibitors Drug Products Offered
12.21.5 Sandoz Recent Development
12.22 Samsung Bioepis
12.22.1 Samsung Bioepis Corporation Information
12.22.2 Samsung Bioepis Business Overview
12.22.3 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.22.4 Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Products Offered
12.22.5 Samsung Bioepis Recent Development
12.23 Sanofi-Aventis
12.23.1 Sanofi-Aventis Corporation Information
12.23.2 Sanofi-Aventis Business Overview
12.23.3 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.23.4 Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Products Offered
12.23.5 Sanofi-Aventis Recent Development
12.24 Shanghai CP Guojian Pharmaceutical
12.24.1 Shanghai CP Guojian Pharmaceutical Corporation Information
12.24.2 Shanghai CP Guojian Pharmaceutical Business Overview
12.24.3 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.24.4 Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Products Offered
12.24.5 Shanghai CP Guojian Pharmaceutical Recent Development
12.25 Shanghai Pharmaceuticals
12.25.1 Shanghai Pharmaceuticals Corporation Information
12.25.2 Shanghai Pharmaceuticals Business Overview
12.25.3 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.25.4 Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Products Offered
12.25.5 Shanghai Pharmaceuticals Recent Development
12.26 Simcere Pharmaceutical
12.26.1 Simcere Pharmaceutical Corporation Information
12.26.2 Simcere Pharmaceutical Business Overview
12.26.3 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.26.4 Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Products Offered
12.26.5 Simcere Pharmaceutical Recent Development
12.27 Toyama Chemical
12.27.1 Toyama Chemical Corporation Information
12.27.2 Toyama Chemical Business Overview
12.27.3 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.27.4 Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Products Offered
12.27.5 Toyama Chemical Recent Development
12.28 Tsumura
12.28.1 Tsumura Corporation Information
12.28.2 Tsumura Business Overview
12.28.3 Tsumura Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.28.4 Tsumura Tumor Necrosis Factor Inhibitors Drug Products Offered
12.28.5 Tsumura Recent Development
12.29 UCB
12.29.1 UCB Corporation Information
12.29.2 UCB Business Overview
12.29.3 UCB Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.29.4 UCB Tumor Necrosis Factor Inhibitors Drug Products Offered
12.29.5 UCB Recent Development
12.30 Zydus Cadila
12.30.1 Zydus Cadila Corporation Information
12.30.2 Zydus Cadila Business Overview
12.30.3 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales, Revenue and Gross Margin (2016-2021)
12.30.4 Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Products Offered
12.30.5 Zydus Cadila Recent Development

13 Tumor Necrosis Factor Inhibitors Drug Manufacturing Cost Analysis
13.1 Tumor Necrosis Factor Inhibitors Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug
13.4 Tumor Necrosis Factor Inhibitors Drug Industrial Chain Analysis

14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Tumor Necrosis Factor Inhibitors Drug Distributors List
14.3 Tumor Necrosis Factor Inhibitors Drug Customers

15 Market Dynamics
15.1 Tumor Necrosis Factor Inhibitors Drug Market Trends
15.2 Tumor Necrosis Factor Inhibitors Drug Drivers
15.3 Tumor Necrosis Factor Inhibitors Drug Market Challenges
15.4 Tumor Necrosis Factor Inhibitors Drug Market Restraints

16 Research Findings and Conclusion

17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Tumor Necrosis Factor Inhibitors Drug Sales (US$ Million) Growth Rate by Type (2016 & 2021 & 2027)
Table 2. Global Tumor Necrosis Factor Inhibitors Drug Sales ((US$ Million)) Comparison by Application (2016 & 2021 & 2027)
Table 3. Global Tumor Necrosis Factor Inhibitors Drug Market Size (US$ Million) by Region: 2016 VS 2021 &2027
Table 4. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Region (2016-2021)
Table 5. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Region (2016-2021)
Table 6. Global Tumor Necrosis Factor Inhibitors Drug Revenue (US$ Million) Market Share by Region (2016-2021))
Table 7. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Region (2016-2021)
Table 8. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) Forecast by Region (2022-2027)
Table 9. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share Forecast by Region (2022-2027)
Table 10. Global Tumor Necrosis Factor Inhibitors Drug Revenue (US$ Million) Forecast by Region (2022-2027)
Table 11. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share Forecast by Region (2022-2027)
Table 12. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) of Key Companies (2016-2021)
Table 13. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Company (2016-2021)
Table 14. Global Tumor Necrosis Factor Inhibitors Drug Revenue (US$ Million) by Company (2016-2021)
Table 15. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Company (2016-2021)
Table 16. Global Tumor Necrosis Factor Inhibitors Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor Inhibitors Drug as of 2020)
Table 17. Global Tumor Necrosis Factor Inhibitors Drug Average Price (USD/Pcs) of Key Company (2016-2021)
Table 18. Manufacturers Tumor Necrosis Factor Inhibitors Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Tumor Necrosis Factor Inhibitors Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Type (2016-2021)
Table 22. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Type (2016-2021)
Table 23. Global Tumor Necrosis Factor Inhibitors Drug Revenue (US$ Million) Market Share by Type (2016-2021)
Table 24. Global Tumor Necrosis Factor Inhibitors Drug Price (USD/Pcs) by Type (2016-2021)
Table 25. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Type (2022-2027)
Table 26. Global Tumor Necrosis Factor Inhibitors Drug Revenue (US$ Million) Market Share by Type (2022-2027)
Table 27. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2022-2027)
Table 28. Global Tumor Necrosis Factor Inhibitors Drug Price (USD/Pcs) by Type (2022-2027)
Table 29. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Application (2016-2021)
Table 30. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Application (2016-2021)
Table 31. Global Tumor Necrosis Factor Inhibitors Drug Revenue (US$ Million) Market Share by Application (2016-2021)
Table 32. Global Tumor Necrosis Factor Inhibitors Drug Price (USD/Pcs) by Application (2016-2021)
Table 33. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Application (2022-2027)
Table 34. Global Tumor Necrosis Factor Inhibitors Drug Sales Share by Application (2022-2027)
Table 35. Global Tumor Necrosis Factor Inhibitors Drug Revenue (US$ Million) Market Share by Application (2022-2027)
Table 36. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Application (2022-2027)
Table 37. Global Tumor Necrosis Factor Inhibitors Drug Price (USD/Pcs) by Application (2022-2027)
Table 38. North America Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Company (2016-2021)
Table 39. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2016-2021)
Table 40. North America Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021) & (US$ Million)
Table 41. North America Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2016-2021)
Table 42. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2016-2021) & (K Pcs)
Table 43. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2016-2021)
Table 44. North America Tumor Necrosis Factor Inhibitors Drug Sales by Type (2022-2027) & (K Pcs)
Table 45. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2022-2027)
Table 46. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2016-2021) & (K Pcs)
Table 47. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2016-2021)
Table 48. North America Tumor Necrosis Factor Inhibitors Drug Sales by Application (2022-2027) & (K Pcs)
Table 49. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2022-2027)
Table 50. Europe Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Company (2016-2021)
Table 51. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2016-2021)
Table 52. Europe Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021) & (US$ Million)
Table 53. Europe Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2016-2021)
Table 54. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2016-2021) & (K Pcs)
Table 55. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2016-2021)
Table 56. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Type (2022-2027) & (K Pcs)
Table 57. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2022-2027)
Table 58. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2016-2021) & (K Pcs)
Table 59. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2016-2021)
Table 60. Europe Tumor Necrosis Factor Inhibitors Drug Sales by Application (2022-2027) & (K Pcs)
Table 61. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2022-2027)
Table 62. China Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Company (2016-2021)
Table 63. China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2016-2021)
Table 64. China Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021) & (US$ Million)
Table 65. China Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2016-2021)
Table 66. China Tumor Necrosis Factor Inhibitors Drug Sales by Type (2016-2021) & (K Pcs)
Table 67. China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2016-2021)
Table 68. China Tumor Necrosis Factor Inhibitors Drug Sales by Type (2022-2027) & (K Pcs)
Table 69. China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2022-2027)
Table 70. China Tumor Necrosis Factor Inhibitors Drug Sales by Application (2016-2021) & (K Pcs)
Table 71. China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2016-2021)
Table 72. China Tumor Necrosis Factor Inhibitors Drug Sales by Application (2022-2027) & (K Pcs)
Table 73. China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2022-2027)
Table 74. Japan Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Company (2016-2021)
Table 75. Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2016-2021)
Table 76. Japan Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021) & (US$ Million)
Table 77. Japan Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2016-2021)
Table 78. Japan Tumor Necrosis Factor Inhibitors Drug Sales by Type (2016-2021) & (K Pcs)
Table 79. Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2016-2021)
Table 80. Japan Tumor Necrosis Factor Inhibitors Drug Sales by Type (2022-2027) & (K Pcs)
Table 81. Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2022-2027)
Table 82. Japan Tumor Necrosis Factor Inhibitors Drug Sales by Application (2016-2021) & (K Pcs)
Table 83. Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2016-2021)
Table 84. Japan Tumor Necrosis Factor Inhibitors Drug Sales by Application (2022-2027) & (K Pcs)
Table 85. Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2022-2027)
Table 86. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Company (2016-2021)
Table 87. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2016-2021)
Table 88. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021) & (US$ Million)
Table 89. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2016-2021)
Table 90. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales by Type (2016-2021) & (K Pcs)
Table 91. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2016-2021)
Table 92. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales by Type (2022-2027) & (K Pcs)
Table 93. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2022-2027)
Table 94. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales by Application (2016-2021) & (K Pcs)
Table 95. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2016-2021)
Table 96. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales by Application (2022-2027) & (K Pcs)
Table 97. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2022-2027)
Table 98. India Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) by Company (2016-2021)
Table 99. India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Company (2016-2021)
Table 100. India Tumor Necrosis Factor Inhibitors Drug Revenue by Company (2016-2021) & (US$ Million)
Table 101. India Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Company (2016-2021)
Table 102. India Tumor Necrosis Factor Inhibitors Drug Sales by Type (2016-2021) & (K Pcs)
Table 103. India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2016-2021)
Table 104. India Tumor Necrosis Factor Inhibitors Drug Sales by Type (2022-2027) & (K Pcs)
Table 105. India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type (2022-2027)
Table 106. India Tumor Necrosis Factor Inhibitors Drug Sales by Application (2016-2021) & (K Pcs)
Table 107. India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2016-2021)
Table 108. India Tumor Necrosis Factor Inhibitors Drug Sales by Application (2022-2027) & (K Pcs)
Table 109. India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application (2022-2027)
Table 110. Apogenix Corporation Information
Table 111. Apogenix Description and Business Overview
Table 112. Apogenix Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 113. Apogenix Tumor Necrosis Factor Inhibitors Drug Product
Table 114. Apogenix Recent Development
Table 115. AryoGen Biopharma Corporation Information
Table 116. AryoGen Biopharma Description and Business Overview
Table 117. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 118. AryoGen Biopharma Tumor Necrosis Factor Inhibitors Drug Product
Table 119. AryoGen Biopharma Recent Development
Table 120. Bionovis Corporation Information
Table 121. Bionovis Description and Business Overview
Table 122. Bionovis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 123. Bionovis Tumor Necrosis Factor Inhibitors Drug Product
Table 124. Bionovis Recent Development
Table 125. CASI Pharmaceuticals Corporation Information
Table 126. CASI Pharmaceuticals Description and Business Overview
Table 127. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 128. CASI Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 129. CASI Pharmaceuticals Recent Development
Table 130. Celltrion Corporation Information
Table 131. Celltrion Description and Business Overview
Table 132. Celltrion Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 133. Celltrion Tumor Necrosis Factor Inhibitors Drug Product
Table 134. Celltrion Recent Development
Table 135. Celgene Corporation Corporation Information
Table 136. Celgene Corporation Description and Business Overview
Table 137. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 138. Celgene Corporation Tumor Necrosis Factor Inhibitors Drug Product
Table 139. Celgene Corporation Recent Development
Table 140. Delenex Therapeutics Corporation Information
Table 141. Delenex Therapeutics Description and Business Overview
Table 142. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 143. Delenex Therapeutics Tumor Necrosis Factor Inhibitors Drug Product
Table 144. Delenex Therapeutics Recent Development
Table 145. Dexa Medica Corporation Information
Table 146. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 147. Dexa Medica Description and Business Overview
Table 148. Dexa Medica Tumor Necrosis Factor Inhibitors Drug Product
Table 149. Dexa Medica Recent Development
Table 150. EPIRUS Biopharmaceuticals Corporation Information
Table 151. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 152. EPIRUS Biopharmaceuticals Description and Business Overview
Table 153. EPIRUS Biopharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 154. EPIRUS Biopharmaceuticals Recent Development
Table 155. Janssen Biotech Corporation Information
Table 156. Janssen Biotech Description and Business Overview
Table 157. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 158. Janssen Biotech Tumor Necrosis Factor Inhibitors Drug Product
Table 159. Janssen Biotech Recent Development
Table 160. GlaxoSmithKline Corporation Information
Table 161. GlaxoSmithKline Description and Business Overview
Table 162. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 163. GlaxoSmithKline Tumor Necrosis Factor Inhibitors Drug Product
Table 164. GlaxoSmithKline Recent Development
Table 165. HanAll Biopharma Corporation Information
Table 166. HanAll Biopharma Description and Business Overview
Table 167. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 168. HanAll Biopharma Tumor Necrosis Factor Inhibitors Drug Product
Table 169. HanAll Biopharma Recent Development
Table 170. Intas Pharmaceuticals Corporation Information
Table 171. Intas Pharmaceuticals Description and Business Overview
Table 172. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 173. Intas Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 174. Intas Pharmaceuticals Recent Development
Table 175. LEO Pharma Corporation Information
Table 176. LEO Pharma Description and Business Overview
Table 177. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 178. LEO Pharma Tumor Necrosis Factor Inhibitors Drug Product
Table 179. LEO Pharma Recent Development
Table 180. LG Life Sciences Corporation Information
Table 181. LG Life Sciences Description and Business Overview
Table 182. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 183. LG Life Sciences Tumor Necrosis Factor Inhibitors Drug Product
Table 184. LG Life Sciences Recent Development
Table 185. MedImmune Corporation Information
Table 186. MedImmune Description and Business Overview
Table 187. MedImmune Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 188. MedImmune Tumor Necrosis Factor Inhibitors Drug Product
Table 189. MedImmune Recent Development
Table 190. Momenta Pharmaceuticals Corporation Information
Table 191. Momenta Pharmaceuticals Description and Business Overview
Table 192. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 193. Momenta Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 194. Momenta Pharmaceuticals Recent Development
Table 195. Novartis Corporation Information
Table 196. Novartis Description and Business Overview
Table 197. Novartis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 198. Novartis Tumor Necrosis Factor Inhibitors Drug Product
Table 199. Novartis Recent Development
Table 200. PROBIOMED Corporation Information
Table 201. PROBIOMED Description and Business Overview
Table 202. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 203. PROBIOMED Tumor Necrosis Factor Inhibitors Drug Product
Table 204. PROBIOMED Recent Development
Table 205. Reliance Life Sciences Corporation Information
Table 206. Reliance Life Sciences Description and Business Overview
Table 207. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 208. Reliance Life Sciences Tumor Necrosis Factor Inhibitors Drug Product
Table 209. Reliance Life Sciences Recent Development
Table 210. Sandoz Corporation Information
Table 211. Sandoz Description and Business Overview
Table 212. Sandoz Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 213. Sandoz Tumor Necrosis Factor Inhibitors Drug Product
Table 214. Sandoz Recent Development
Table 215. Samsung Bioepis Corporation Information
Table 216. Samsung Bioepis Description and Business Overview
Table 217. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 218. Samsung Bioepis Tumor Necrosis Factor Inhibitors Drug Product
Table 219. Samsung Bioepis Recent Development
Table 220. Sanofi-Aventis Corporation Information
Table 221. Sanofi-Aventis Description and Business Overview
Table 222. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 223. Sanofi-Aventis Tumor Necrosis Factor Inhibitors Drug Product
Table 224. Sanofi-Aventis Recent Development
Table 225. Shanghai CP Guojian Pharmaceutical Corporation Information
Table 226. Shanghai CP Guojian Pharmaceutical Description and Business Overview
Table 227. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 228. Shanghai CP Guojian Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product
Table 229. Shanghai CP Guojian Pharmaceutical Recent Development
Table 230. Shanghai Pharmaceuticals Corporation Information
Table 231. Shanghai Pharmaceuticals Description and Business Overview
Table 232. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 233. Shanghai Pharmaceuticals Tumor Necrosis Factor Inhibitors Drug Product
Table 234. Shanghai Pharmaceuticals Recent Development
Table 235. Simcere Pharmaceutical Corporation Information
Table 236. Simcere Pharmaceutical Description and Business Overview
Table 237. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 238. Simcere Pharmaceutical Tumor Necrosis Factor Inhibitors Drug Product
Table 239. Simcere Pharmaceutical Recent Development
Table 240. Toyama Chemical Corporation Information
Table 241. Toyama Chemical Description and Business Overview
Table 242. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 243. Toyama Chemical Tumor Necrosis Factor Inhibitors Drug Product
Table 244. Toyama Chemical Recent Development
Table 245. Tsumura Corporation Information
Table 246. Tsumura Description and Business Overview
Table 247. Tsumura Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 248. Tsumura Tumor Necrosis Factor Inhibitors Drug Product
Table 249. Tsumura Recent Development
Table 250. UCB Corporation Information
Table 251. UCB Description and Business Overview
Table 252. UCB Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 253. UCB Tumor Necrosis Factor Inhibitors Drug Product
Table 254. UCB Recent Development
Table 255. Zydus Cadila Corporation Information
Table 256. Zydus Cadila Description and Business Overview
Table 257. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2016-2021)
Table 258. Zydus Cadila Tumor Necrosis Factor Inhibitors Drug Product
Table 259. Zydus Cadila Recent Development
Table 260. Production Base and Market Concentration Rate of Raw Material
Table 261. Key Suppliers of Raw Materials
Table 262. Tumor Necrosis Factor Inhibitors Drug Distributors List
Table 263. Tumor Necrosis Factor Inhibitors Drug Customers List
Table 264. Tumor Necrosis Factor Inhibitors Drug Market Trends
Table 265. Tumor Necrosis Factor Inhibitors Drug Market Drivers
Table 266. Tumor Necrosis Factor Inhibitors Drug Market Challenges
Table 267. Tumor Necrosis Factor Inhibitors Drug Market Restraints
Table 268. Research Programs/Design for This Report
Table 269. Key Data Information from Secondary Sources
Table 270. Key Data Information from Primary Sources
List of Figures
Figure 1. Tumor Necrosis Factor Inhibitors Drug Product Picture
Figure 2. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2021 & 2027
Figure 3. Cimzia (Certolizumab Pegol) Product Picture
Figure 4. Enbrel (Etanercept) Product Picture
Figure 5. Humira ( Adalimumab) Product Picture
Figure 6. Otezla (Apremilast) Product Picture
Figure 7. Remicade (Infliximab) Product Picture
Figure 8. Simponi (Golimumab) Product Picture
Figure 9. Global Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2021 & 2027
Figure 10. Clinic Examples
Figure 11. Hospital Examples
Figure 12. Others Examples
Figure 13. Global Tumor Necrosis Factor Inhibitors Drug Sales, (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Tumor Necrosis Factor Inhibitors Drug Sales Growth Rate (2016-2027) & (US$ Million)
Figure 15. Global Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) Growth Rate (2016-2027)
Figure 16. Global Tumor Necrosis Factor Inhibitors Drug Price Trends Growth Rate (2016-2027) (USD/Pcs)
Figure 17. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region: 2016 VS 2021
Figure 18. Global Tumor Necrosis Factor Inhibitors Drug Revenue Market Share by Region: 2021 VS 2027
Figure 19. North America Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 20. North America Tumor Necrosis Factor Inhibitors Drug Sales (K Pcs) Growth Rate (2016-2027)
Figure 21. Europe Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 22. Europe Tumor Necrosis Factor Inhibitors Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 23. China Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 24. China Tumor Necrosis Factor Inhibitors Drug Sales (Million USD) and Growth Rate (2016-2027)
Figure 25. Japan Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 26. Japan Tumor Necrosis Factor Inhibitors Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 27. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 28. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 29. India Tumor Necrosis Factor Inhibitors Drug Revenue (Million USD) Growth Rate (2016-2027)
Figure 30. India Tumor Necrosis Factor Inhibitors Drug Sales (Million USD) Growth Rate (2016-2027)
Figure 31. Global 5 Largest Tumor Necrosis Factor Inhibitors Drug Players Market Share by Revenue in Tumor Necrosis Factor Inhibitors Drug: 2016 & 2020
Figure 32. Tumor Necrosis Factor Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 33. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Type (2016-2021)
Figure 34. Global Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate by Type in 2016 & 2020
Figure 35. Global Tumor Necrosis Factor Inhibitors Drug Revenue Share by Application (2016-2021)
Figure 36. Global Tumor Necrosis Factor Inhibitors Drug Revenue Growth Rate by Application in 2016 & 2020
Figure 37. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2020
Figure 38. North America Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2020
Figure 39. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2020
Figure 40. Europe Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2020
Figure 41. China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2020
Figure 42. China Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2020
Figure 43. Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2020
Figure 44. Japan Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2020
Figure 45. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2020
Figure 46. Southeast Asia Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2020
Figure 47. India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Type in 2020
Figure 48. India Tumor Necrosis Factor Inhibitors Drug Sales Market Share by Application in 2020
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Tumor Necrosis Factor Inhibitors Drug
Figure 51. Manufacturing Process Analysis of Tumor Necrosis Factor Inhibitors Drug
Figure 52. Tumor Necrosis Factor Inhibitors Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Bottom-up and Top-down Approaches for This Report
Figure 56. Data Triangulation
Figure 57. Key Executives Interviewed